KR20210137110A - Mhc 클래스 ii 모델을 사용한 신생항원 동정 - Google Patents

Mhc 클래스 ii 모델을 사용한 신생항원 동정 Download PDF

Info

Publication number
KR20210137110A
KR20210137110A KR1020217031933A KR20217031933A KR20210137110A KR 20210137110 A KR20210137110 A KR 20210137110A KR 1020217031933 A KR1020217031933 A KR 1020217031933A KR 20217031933 A KR20217031933 A KR 20217031933A KR 20210137110 A KR20210137110 A KR 20210137110A
Authority
KR
South Korea
Prior art keywords
allele
mhc
peptide
presentation
neoantigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217031933A
Other languages
English (en)
Korean (ko)
Inventor
토마스 프란시스 바우처
브렌던 불릭-술리반
제니퍼 버스비
민 덕 카오
매튜 조셉 데이비스
로렌 엘리자베스 영
조슈아 마이클 프란시스
크리스틴 팔머
모카 스코베르네
로만 엘렌스키
Original Assignee
그릿스톤 바이오, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그릿스톤 바이오, 인코포레이티드 filed Critical 그릿스톤 바이오, 인코포레이티드
Publication of KR20210137110A publication Critical patent/KR20210137110A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/044—Recurrent networks, e.g. Hopfield networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/044—Recurrent networks, e.g. Hopfield networks
    • G06N3/0442—Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
    • G06N3/0445—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/045—Combinations of networks
    • G06N3/0454—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/0464—Convolutional networks [CNN, ConvNet]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/082—Learning methods modifying the architecture, e.g. adding, deleting or silencing nodes or connections
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/09—Supervised learning
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/048—Activation functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
  • Computational Linguistics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
KR1020217031933A 2019-03-06 2020-03-06 Mhc 클래스 ii 모델을 사용한 신생항원 동정 Pending KR20210137110A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814801P 2019-03-06 2019-03-06
US62/814,801 2019-03-06
US201962826822P 2019-03-29 2019-03-29
US62/826,822 2019-03-29
PCT/US2020/021508 WO2020181240A1 (en) 2019-03-06 2020-03-06 Identification of neoantigens with mhc class ii model

Publications (1)

Publication Number Publication Date
KR20210137110A true KR20210137110A (ko) 2021-11-17

Family

ID=72338461

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031933A Pending KR20210137110A (ko) 2019-03-06 2020-03-06 Mhc 클래스 ii 모델을 사용한 신생항원 동정

Country Status (10)

Country Link
US (1) US20220154281A1 (https=)
EP (1) EP3935071A4 (https=)
JP (2) JP7668742B2 (https=)
KR (1) KR20210137110A (https=)
CN (1) CN113711239A (https=)
AU (1) AU2020232844A1 (https=)
CA (1) CA3132041A1 (https=)
IL (1) IL286086A (https=)
TW (1) TWI894138B (https=)
WO (1) WO2020181240A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US11848073B2 (en) * 2019-04-03 2023-12-19 University Of Central Florida Research Foundation, Inc. Methods and system for efficient indexing for genetic genealogical discovery in large genotype databases
SG11202110956RA (en) 2019-04-05 2021-10-28 Rootpath Genomics Inc Compositions and methods for t-cell receptor gene assembly
US11644470B2 (en) * 2019-04-15 2023-05-09 Bioinformatics Solutions Inc. Systems and methods for de novo peptide sequencing using deep learning and spectrum pairs
US11727284B2 (en) * 2019-12-12 2023-08-15 Business Objects Software Ltd Interpretation of machine learning results using feature analysis
WO2022087380A1 (en) * 2020-10-23 2022-04-28 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
CN112910288B (zh) * 2020-12-08 2022-08-09 上海交通大学 一种基于逆变器散热器温度预测的过温预警方法
CN113255690B (zh) * 2021-04-15 2022-04-12 南昌大学 一种基于轻量级卷积神经网络的复合绝缘子憎水性检测方法
CN113160887B (zh) * 2021-04-23 2022-06-14 哈尔滨工业大学 一种融合了单细胞tcr测序数据的肿瘤新生抗原筛选方法
CN116264103A (zh) * 2021-12-14 2023-06-16 深圳华大基因股份有限公司 构建机器学习模型的方法、系统及用途
CN114023387B (zh) * 2022-01-05 2022-04-22 山东建筑大学 一种基于卷积神经网络的细胞反卷积预测方法
WO2023146978A2 (en) * 2022-01-26 2023-08-03 Memorial Sloan-Kettering Cancer Center Systems and methods for determining t-cell cross-reactivity between antigens
CN114446385B (zh) * 2022-01-29 2024-08-13 杭州纽安津生物科技有限公司 Hla ii型分子与多肽的亲和力预测模型的获取方法及装置
WO2023172633A1 (en) * 2022-03-08 2023-09-14 Avalo, Inc. System and method for genomic association
WO2023215358A1 (en) * 2022-05-03 2023-11-09 3T Biosciences, Inc. T-cell target discovery
CN115295084B (zh) * 2022-08-05 2026-03-17 南开大学 一种肿瘤新抗原免疫组库数据可视化分析方法和系统
EP4570907A1 (en) * 2022-08-08 2025-06-18 Sapporo Medical University Method for selecting subject-derived neoantigen
AU2023321890A1 (en) * 2022-08-12 2025-02-27 Biontech Us Inc. Methods and systems for prediction of hla epitopes
EP4680270A1 (en) * 2023-03-13 2026-01-21 Seattle Project Corp. Epitope prediction via a learned genotype network across class ii mhc alleles
CN116469457B (zh) * 2023-06-14 2023-10-13 普瑞基准科技（北京）有限公司 Mhc与抗原多肽结合、呈递及免疫原性的预测模型训练方法和装置
CN117912568B (zh) * 2024-01-05 2024-08-06 中山大学 H9n2亚型禽流感毒株抗原性快速鉴别方法及装置
CN120089201B (zh) * 2025-04-30 2025-07-04 广东省农业科学院动物卫生研究所 一种基于深度学习的通用表位多肽筛选方法和系统
CN120600110B (zh) * 2025-08-06 2025-12-09 上海交通大学医学院附属仁济医院 基于人工智能的多变病原t细胞表位精准筛选方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CN107002038B (zh) * 2014-09-17 2021-10-15 约翰·霍普金斯大学 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR102841050B1 (ko) * 2017-04-19 2025-08-01 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
CN109145927A (zh) * 2017-06-16 2019-01-04 杭州海康威视数字技术股份有限公司 一种对形变图像的目标识别方法及装置

Also Published As

Publication number Publication date
JP2025114587A (ja) 2025-08-05
TW202100168A (zh) 2021-01-01
EP3935071A4 (en) 2022-12-21
JP2022524328A (ja) 2022-05-02
US20220154281A1 (en) 2022-05-19
AU2020232844A1 (en) 2021-10-28
IL286086A (en) 2021-10-31
WO2020181240A8 (en) 2021-09-16
CN113711239A (zh) 2021-11-26
CA3132041A1 (en) 2020-09-10
WO2020181240A1 (en) 2020-09-10
EP3935071A1 (en) 2022-01-12
TWI894138B (zh) 2025-08-21
JP7668742B2 (ja) 2025-04-25

Similar Documents

Publication Publication Date Title
JP7712970B2 (ja) ホットスポットを利用した新生抗原の特定
JP7668742B2 (ja) Ｍｈｃクラスｉｉモデルによる新生抗原の特定
KR102930070B1 (ko) 범-대립유전자 모델을 갖는 신생항원 동정
KR102946326B1 (ko) T-세포 요법을 위한 신생항원 동정
JP7851893B2 (ja) Ｔ細胞療法用の新生抗原の特定法
KR20260057650A (ko) T-세포 요법을 위한 신생항원 동정
HK40034414A (en) Neoantigen identification using hotspots
HK40034414B (en) Neoantigen identification using hotspots

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000